Targeting gdf6 and bmp signaling for anti-melanoma therapy

Patent metadata

Field	Value
Publication number	US-2020246438-A1
Application number	US-201916707543-A
Country	US
Kind code	A1
Filing date	Dec 9, 2019
Priority date	Mar 10, 2015
Publication date	Aug 6, 2020
Grant date	—

Abstract

The invention features methods of treating melanoma by modulating an activity of GDF6 in melanoma cells. In one aspect, the methods involve downregulating an activity of GDF6, for example, by using an anti-GDF6 binding molecule, such as an inactivating antibody. Another aspect features treating a subject by first screening for the presence of GDF6 and then treating the subject with an inhibitor of a GDF6 activity. Screening assays for identification of modulators of an activity of GDF6 are also featured.

First claim

1 . A method of treating a melanoma in a subject, the method comprising administering to a subject in need thereof an effective amount of an inhibitor of at least one GDF6 activity.

2 . The method of claim 1 , wherein the subject is a non-human mammal, or wherein the subject is a human.

3 . (canceled)

4 . The method of claim 1 , wherein:
inhibiting the at least one GDF6 activity comprises apoptosis of at least one melanoma cell; inhibiting the at least one GDF6 activity comprises reducing downstream signaling from a BMP receptor with which the GDF6 interacts when compared to a suitable control, optionally wherein the reducing downstream signaling comprises reducing SMAD1/5/8 phosphorylation; or the inhibitor is selected from the group consisting of an antibody, an antibody fragment, an antisense nucleic acid, a soluble receptor polypeptide, and a small molecule.

5 - 7 . (canceled)

8 . The method of claim 4 , wherein the antisense nucleic acid is selected from the group consisting of a RNAi, a ribozyme, an α-anomeric nucleic acid molecule, and a peptide nucleic acid, optionally wherein:
the antisense molecule is an RNAi molecule and is a siRNA or a shRNA;
the soluble receptor polypeptide comprises an ALK3 polypeptide; or
the soluble receptor polypeptide comprises an ALK3(24-152)-Fc fusion polypeptide comprising an amino acid sequence of SEQ ID NO:9.

9 - 11 . (canceled)

12 . A screening assay method for identifying a compound that decreases GDF6 activity, comprising
(a) providing an in vitro composition that comprises at least one melanoma cell; (b) contacting the composition with a test compound; and (c) determining an effect of the test compound on an activity of GDF6 in the composition, wherein a decrease in the activity of GDF6 in the presence of the compound, relative to a suitable control, identifies the compound as one that decreases GDF6 activity.

13 . The method of claim 12 , wherein decreasing an activity of GDF6 comprises:
apoptosis of at least one melanoma cell in the composition; or reducing downstream signaling from a BMP receptor with which the GDF6 interacts.

14 . (canceled)

15 . The method of claim 13 , wherein the reduced downstream signaling comprises reducing SMAD1/5/8 phosphorylation.

16 . The method of claim 12 , wherein the test compound is selected from the group consisting of an antibody, an antibody fragment, antisense nucleic acid, a soluble receptor polypeptide and a small molecule.

17 . The method of claim 16 , wherein the antisense nucleic acid is selected from the group consisting of a RNAi, a ribozyme, an α-anomeric nucleic acid molecule, and a peptide nucleic acid, optionally wherein:
the antisense molecule is an RNAi molecule and is a siRNA or a shRNA;
the soluble receptor polypeptide comprises an ALK3 polypeptide; or
the soluble receptor polypeptide comprises an ALK3(24-152)-Fc fusion polypeptide comprising an amino acid sequence of SEQ ID NO:9.

18 - 20 . (canceled)

21 . A screening assay method for identifying a compound that decreases a GDF6 activity, comprising
(a) providing a subject that comprises at least one melanoma cell; (b) administering to the subject a test compound; and (c) determining an effect of the test compound on an activity of GDF6 in the subject, wherein a decrease in the activity of GDF6 in the presence of the compound, relative to a suitable control, identifies the compound as one that decreases GDF6 activity.

22 . The method of claim 21 , wherein decreasing an activity of GDF6 comprises:
apoptosis of at least one melanoma cell; or reducing downstream signaling from a BMP receptor with which the GDF6 interacts.

23 . (canceled)

24 . The method of claim 22 , wherein the reduced downstream signaling comprises reducing SMAD1/5/8 phosphorylation.

25 . The method of claim 21 , wherein the test compound is selected from the group consisting of an antibody, an antibody fragment, antisense nucleic acid, and a small molecule.

26 . The method of claim 25 , wherein the antisense nucleic acid is selected from the group consisting of a RNAi, a ribozyme, an α-anomeric nucleic acid molecule, and a peptide nucleic acid, optionally wherein:
the antisense molecule is an RNAi molecule and is a siRNA or a shRNA;
the soluble receptor polypeptide comprises an ALK3 polypeptide; or
the soluble receptor polypeptide comprises an ALK3(24-152)-Fc fusion polypeptide comprising an amino acid sequence of SEQ ID NO:9.

27 - 29 . (canceled)

30 . A method of treating melanoma in a subject, comprising administering to the subject the compound of claim 12 .

31 . The use of the compound of claim 30 , wherein the subject is a non-human mammal, or wherein the subject is a human.

32 . (canceled)

33 . A method of inhibiting melanoma formation in a subject at risk for melanoma formation, comprising administering to the subject an effective amount of an inhibitor of a GDF6 activity.

34 . The method of claim 33 , wherein:
the subject is a non-human mammal, or wherein the subject is a human; inhibiting the at least one GDF6 activity comprises apoptosis of at least one melanoma cell; inhibiting the at least one GDF6 activity comprises reducing downstream signaling from a BMP receptor with which the GDF6 interacts when compared to a suitable control, optionally wherein the reducing downstream signaling comprises reducing SMAD1/5/8 phosphorylation; the inhibitor is selected from the group consisting of an antibody, an antibody fragment, antisense nucleic acid, a soluble receptor polypeptide, and a small molecule; wherein the antisense nucleic acid is selected from the group consisting of a RNAi, a ribozyme, an α-anomeric nucleic acid molecule, and a peptide nucleic acid, optionally wherein the antisense molecule is an RNAi molecule and is a siRNA or a shRNA; or the soluble receptor polypeptide comprises an ALK3 polypeptide, optionally wherein the soluble receptor polypeptide comprises an ALK3(24-152)-Fc fusion polypeptide comprising an amino acid sequence of SEQ ID NO:9.

35 - 43 . (canceled)

44 . A method of treating a melanoma in a subject, comprising
(a) obtaining a sample from a suspected area of the subject's skin; (b) determining the presence of GDF6; (c) obtaining a suitable control; (d) comparing the presence of GDF6 in the sample of step (b) with the suitable control of step (c); (e) determining if the subject displays a melanoma, wherein the presence of GDF6 in the sample but not in the suitable control indicates melanoma; (f) treating the subject with a GDF6 inhibitor to inhibit an activity of the GDF6 if the subject has melanoma.

45 . The method of claim 44 , wherein:
the subject is a non-human mammal, or wherein the subject is human; inhibiting the at least one GDF6 activity comprises apoptosis of at least one melanoma cell; inhibiting the at least one GDF6 activity comprises reducing downstream signaling from a BMP receptor with which the GDF6 interacts when compared to a suitable control, optionally wherein the reducing downstream signaling comprises reducing SMAD1/5/8 phosphorylation; the inhibitor is selected from the group consisting of an antibody, an antibody fragment, antisense nucleic acid, a soluble receptor polypeptide, and a small molecule, optionally wherein the antisense nucleic acid is selected from the group co

Assignees

• Univ Massachusetts

Inventors

• Ceol Craig Joseph
• Venkatesan Arvind Murali

Classifications

• G01N33/5751

  of the skin, e.g. melanoma · CPC title

• A61K38/179 Primary

  for growth factors; for growth regulators · CPC title

• C12N15/113

  Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title

• A61K31/713

  Double-stranded nucleic acids or oligonucleotides · CPC title

• C07K2319/30

  Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title